Identification of Stem-Like Cells in Atrial Myxoma by Markers CD44, CD19, and CD45

<div>Multipotent capacity of myxoma derived cells. Immunostaining of subcultured myxoma derived phase-bright cells with connexin 43, myocyte enhancer factor 2C (MEF-2C), cardiac troponin T (cTnT), and <i>α</i>-smooth muscle actin (<i>α</i>-SMA). Scale bar = 10 <i>μ</i>m.</div>

Stem Cells International

fig3

Figure 3

Figure 3: Identification of Stem-Like Cells in Atrial Myxoma by Markers CD44, CD19, and CD45 